bicalutamide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
non-steroid antiandrogens	367	90357-06-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: ICI 176334 ICI-176334 bicalutamide casodex	Bicalutamide is a non-steroidal androgen receptor inhibitor. It competitively inhibits the action of androgens by binding to cytosol androgen receptors in the target tissue. Prostatic carcinoma is known to be androgen sensitive and responds to treatment that counteracts the effect of androgen and/or removes the source of androgen. Molecular weight: 430.37 Formula: C18H14F4N2O4S CLOGP: 2.71 LIPINSKI: 0 HAC: 6 HDO: 2 TPSA: 107.26 ALOGS: -4.67 ROTB: 6 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

ICI 176334
ICI-176334
bicalutamide
casodex

Bicalutamide is a non-steroidal androgen receptor inhibitor. It competitively inhibits the action of androgens by binding to cytosol androgen receptors in the target tissue. Prostatic carcinoma is known to be androgen sensitive and responds to treatment that counteracts the effect of androgen and/or removes the source of androgen.

Molecular weight: 430.37
Formula: C18H14F4N2O4S
CLOGP: 2.71
LIPINSKI: 0
HAC: 6
HDO: 2
TPSA: 107.26
ALOGS: -4.67
ROTB: 6

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
50	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.01 mg/mL	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	1.94 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

Date	Agency	Company	Orphan
Oct. 4, 1995	FDA	ASTRAZENECA

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Prostatic specific antigen increased	1075.82	12.95	404	25135	14276	34917116
Metastases to bone	385.89	12.95	184	25355	11786	34919606
Osteonecrosis of jaw	351.18	12.95	197	25342	17692	34913700
Prostate cancer metastatic	340.25	12.95	136	25403	5667	34925725
Prostate cancer	329.62	12.95	255	25284	39394	34891998
Hot flush	265.41	12.95	165	25374	17901	34913491
Interstitial lung disease	259.03	12.95	277	25262	65005	34866387
Malignant neoplasm progression	250.98	12.95	315	25224	87731	34843661
Hormone-refractory prostate cancer	128.43	12.95	39	25500	701	34930691
Osteonecrosis	106.96	12.95	88	25451	14802	34916590
Prostate cancer recurrent	93.08	12.95	33	25506	980	34930412
Blood testosterone increased	92.93	12.95	35	25504	1238	34930154
Bone lesion	78.86	12.95	40	25499	2923	34928469
Haematuria	76.75	12.95	134	25405	49932	34881460
Prostatic specific antigen abnormal	76.02	12.95	26	25513	692	34930700
Torsade de pointes	74.68	12.95	53	25486	7156	34924236
Toxicity to various agents	69.10	12.95	30	25509	200332	34731060
Tooth extraction	63.92	12.95	41	25498	4687	34926705
Bone disorder	62.79	12.95	45	25494	6170	34925222
Metastases to lymph nodes	61.45	12.95	40	25499	4688	34926704
Drug abuse	59.94	12.95	3	25536	99093	34832299
Gynaecomastia	58.56	12.95	53	25486	10127	34921265
Hepatic function abnormal	54.52	12.95	108	25431	44255	34887137
Bone pain	52.48	12.95	70	25469	20616	34910776
Breast cancer male	51.80	12.95	17	25522	397	34930995
Metastasis	51.28	12.95	34	25505	4110	34927282
Blood testosterone abnormal	50.86	12.95	17	25522	421	34930971
Hypocalcaemia	49.48	12.95	74	25465	24215	34907177
Hydronephrosis	48.32	12.95	48	25491	10298	34921094
Metastases to spine	46.73	12.95	27	25512	2557	34928835
Disease progression	46.66	12.95	179	25360	107898	34823494
Completed suicide	46.25	12.95	8	25531	98160	34833232
Metastases to lung	44.94	12.95	44	25495	9276	34922116
Anti-androgen withdrawal syndrome	44.76	12.95	8	25531	7	34931385
Exposed bone in jaw	43.93	12.95	22	25517	1564	34929828
Urinary retention	39.45	12.95	84	25455	36204	34895188
Pain in jaw	37.57	12.95	47	25492	12993	34918399
Anaemia	35.91	12.95	292	25247	233043	34698349
Breast tenderness	34.80	12.95	15	25524	756	34930636
Injection site induration	34.27	12.95	23	25516	2837	34928555
Cardiac failure	33.68	12.95	144	25395	91104	34840288
Pituitary haemorrhage	32.41	12.95	10	25529	190	34931202
Metastases to liver	31.28	12.95	44	25495	13619	34917773
Osteomyelitis	31.21	12.95	48	25491	16088	34915304
Electrocardiogram QT prolonged	30.65	12.95	82	25457	40870	34890522
Polyneuropathy in malignant disease	30.41	12.95	10	25529	235	34931157
Central nervous system mass	29.22	12.95	9	25530	170	34931222
Wall motion score index abnormal	29.07	12.95	9	25530	173	34931219
Breast swelling	28.76	12.95	10	25529	280	34931112
Asthenia	28.09	12.95	288	25251	244963	34686429
Spinal cord compression	27.51	12.95	23	25516	3952	34927440
Urinary tract obstruction	27.26	12.95	22	25517	3598	34927794
Retroperitoneal lymphadenopathy	27.10	12.95	13	25526	841	34930551
Sequestrectomy	26.81	12.95	9	25530	226	34931166
Airway remodelling	26.66	12.95	9	25530	230	34931162
Atopy	26.19	12.95	9	25530	243	34931149
Muscular weakness	26.09	12.95	114	25425	72783	34858609
Hyperthyroidism	25.64	12.95	35	25504	10531	34920861
Neuroendocrine carcinoma of prostate	25.31	12.95	5	25534	11	34931381
Bone sequestrum	25.21	12.95	11	25528	571	34930821
Intercepted product preparation error	24.97	12.95	22	25517	4056	34927336
Osteosclerosis	24.38	12.95	14	25525	1310	34930082
Cystitis radiation	24.29	12.95	7	25532	104	34931288
Injection site abscess	24.17	12.95	12	25527	837	34930555
Cardiac septal defect	24.12	12.95	9	25530	310	34931082
Off label use	24.02	12.95	194	25345	419330	34512062
Blood alkaline phosphatase increased	23.91	12.95	63	25476	31112	34900280
Gingivitis	23.33	12.95	20	25519	3555	34927837
COVID-19	23.12	12.95	14	25525	77536	34853856
Radiation injury	22.94	12.95	10	25529	518	34930874
Phyllodes tumour	22.65	12.95	4	25535	3	34931389
Cerebral infarction	22.62	12.95	57	25482	27398	34903994
Abscess jaw	22.41	12.95	11	25528	749	34930643
Osteitis	21.90	12.95	14	25525	1590	34929802
Testicular atrophy	21.84	12.95	10	25529	582	34930810
Metastases to eye	21.70	12.95	6	25533	76	34931316
Neuroendocrine carcinoma	21.57	12.95	9	25530	418	34930974
Metastases to soft tissue	21.39	12.95	9	25530	427	34930965
Cholangitis sclerosing	20.90	12.95	13	25526	1408	34929984
Metastases to breast	20.85	12.95	4	25535	7	34931385
Troponin increased	20.80	12.95	33	25506	11356	34920036
Decreased appetite	20.76	12.95	199	25340	166193	34765199
Loss of libido	20.26	12.95	16	25523	2536	34928856
Bone debridement	20.03	12.95	7	25532	199	34931193
Toothache	19.98	12.95	24	25515	6364	34925028
Product monitoring error	19.85	12.95	20	25519	4361	34927031
Infusion related reaction	19.80	12.95	7	25532	53050	34878342
Cancer pain	19.62	12.95	16	25523	2656	34928736
Eosinophilic myocarditis	19.35	12.95	9	25530	543	34930849
Hyperadrenalism	19.07	12.95	5	25534	51	34931341
Radiation proctitis	19.02	12.95	6	25533	123	34931269
Dysuria	18.94	12.95	53	25486	27099	34904293
Radical prostatectomy	18.90	12.95	5	25534	53	34931339
Fatigue	18.76	12.95	377	25162	370276	34561116
Anaesthesia	18.73	12.95	5	25534	55	34931337
Disseminated intravascular coagulation	18.71	12.95	46	25493	21770	34909622
Product dose omission issue	18.68	12.95	37	25502	119674	34811718
Bone trimming	18.67	12.95	3	25536	0	34931392
Androgens increased	18.67	12.95	3	25536	0	34931392
Purulent discharge	18.65	12.95	16	25523	2847	34928545
Conjunctival ulcer	18.49	12.95	5	25534	58	34931334
Bone swelling	18.47	12.95	7	25532	252	34931140
Pneumonia	18.37	12.95	173	25366	362454	34568938
Breast pain	18.36	12.95	12	25527	1416	34929976
Adrenal insufficiency	18.21	12.95	35	25504	14012	34917380
Jaw disorder	18.06	12.95	14	25525	2161	34929231
Abdominal wall haematoma	17.86	12.95	13	25526	1824	34929568
Haemorrhage urinary tract	17.63	12.95	13	25526	1861	34929531
Gingival swelling	17.21	12.95	11	25528	1249	34930143
Back pain	16.87	12.95	149	25390	121640	34809752
Cough	16.78	12.95	55	25484	150085	34781307
Bone fistula	16.72	12.95	4	25535	27	34931365
Sepsis	16.63	12.95	64	25475	166497	34764895
Ureteric rupture	16.59	12.95	3	25536	3	34931389
Drug hypersensitivity	16.23	12.95	21	25518	80508	34850884
Intentional product use issue	16.21	12.95	12	25527	59804	34871588
Rheumatoid arthritis	16.17	12.95	4	25535	38234	34893158
Overdose	16.13	12.95	26	25513	91033	34840359
Breakthrough pain	15.94	12.95	8	25531	571	34930821
Respiratory symptom	15.87	12.95	12	25527	1785	34929607
Quality of life decreased	15.86	12.95	17	25522	3984	34927408
Oral surgery	15.81	12.95	8	25531	581	34930811
Hydroureter	15.70	12.95	7	25532	383	34931009
Debridement	15.18	12.95	9	25530	894	34930498
Neuroendocrine carcinoma metastatic	15.15	12.95	5	25534	119	34931273
Prescribed underdose	15.11	12.95	25	25514	8908	34922484
Injection site ulcer	14.86	12.95	6	25533	256	34931136
Microangiopathy	14.72	12.95	9	25530	945	34930447
Pathological fracture	14.56	12.95	17	25522	4374	34927018
Pelvic pain	14.43	12.95	13	25526	2467	34928925
Eye colour change	14.42	12.95	6	25533	277	34931115
Oral infection	14.30	12.95	12	25527	2071	34929321
Dental care	14.21	12.95	6	25533	287	34931105
Syringe issue	14.10	12.95	19	25520	5645	34925747
Urogenital haemorrhage	14.05	12.95	8	25531	737	34930655
Orchidectomy	14.03	12.95	4	25535	57	34931335
Therapeutic product effect incomplete	13.88	12.95	10	25529	50531	34880861
Prostatic specific antigen decreased	13.87	12.95	5	25534	156	34931236
Paraneoplastic dermatomyositis	13.84	12.95	4	25535	60	34931332
Death	13.72	12.95	384	25155	397665	34533727
Metastases to spinal cord	13.66	12.95	3	25536	13	34931379
Coccydynia	13.53	12.95	7	25532	533	34930859
Vipoma	13.47	12.95	3	25536	14	34931378
Product name confusion	13.38	12.95	4	25535	68	34931324
Device leakage	13.34	12.95	20	25519	6555	34924837
Allodynia	13.24	12.95	8	25531	823	34930569
Suicide attempt	13.22	12.95	6	25533	39110	34892282
Gingival abscess	13.19	12.95	5	25534	180	34931212
Poor peripheral circulation	13.17	12.95	10	25529	1497	34929895
Rash	13.16	12.95	102	25437	222650	34708742

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Prostatic specific antigen increased	1190.31	13.67	315	20346	10071	79713656
Prostate cancer	460.57	13.67	207	20454	33061	79690666
Osteonecrosis of jaw	304.20	13.67	170	20491	43056	79680671
Metastases to bone	291	13.67	137	20524	24290	79699437
Prostate cancer metastatic	290.65	13.67	85	20576	3922	79719805
Interstitial lung disease	279.22	13.67	232	20429	112368	79611359
Malignant neoplasm progression	220.86	13.67	221	20440	135769	79587958
Hot flush	172.24	13.67	130	20531	54747	79668980
Hormone-refractory prostate cancer	125.00	13.67	28	20633	432	79723295
Blood testosterone increased	116.05	13.67	31	20630	1021	79722706
Haematuria	111.83	13.67	112	20549	68724	79655003
Prostate cancer recurrent	104.11	13.67	27	20634	791	79722936
Gynaecomastia	82.05	13.67	40	20621	7641	79716086
Torsade de pointes	79.52	13.67	54	20607	19258	79704469
Disease progression	76.68	13.67	156	20505	184206	79539521
Hepatic function abnormal	74.06	13.67	93	20568	73014	79650713
Prostatic specific antigen abnormal	67.42	13.67	17	20644	444	79723283
Urinary retention	67.09	13.67	78	20583	56552	79667175
Osteonecrosis	60.69	13.67	56	20605	31039	79692688
Anaemia	58.45	13.67	249	20412	444766	79278961
Death	56.14	13.67	292	20369	566222	79157505
Metastasis	53.69	13.67	29	20632	6851	79716876
Anti-androgen withdrawal syndrome	53.04	13.67	8	20653	7	79723720
Hypocalcaemia	51.33	13.67	64	20597	49860	79673867
Cardiac failure	50.66	13.67	119	20542	154723	79569004
Metastases to lung	50.34	13.67	40	20621	18123	79705604
Metastases to lymph nodes	49.91	13.67	32	20629	10365	79713362
Hydronephrosis	49.58	13.67	39	20622	17415	79706312
Bone lesion	43.56	13.67	24	20637	5895	79717832
Intercepted product preparation error	42.46	13.67	20	20641	3540	79720187
Rheumatoid arthritis	42.40	13.67	3	20658	208467	79515260
Completed suicide	41.30	13.67	7	20654	245760	79477967
Toxicity to various agents	40.61	13.67	30	20631	421510	79302217
Infusion related reaction	39.94	13.67	6	20655	230231	79493496
Polyneuropathy in malignant disease	39.06	13.67	10	20651	278	79723449
Asthenia	38.96	13.67	246	20415	511443	79212284
Wall motion score index abnormal	38.31	13.67	9	20652	173	79723554
Pituitary haemorrhage	38.29	13.67	10	20651	301	79723426
Central nervous system mass	38.26	13.67	9	20652	174	79723553
Breast cancer male	37.62	13.67	10	20651	323	79723404
Alopecia	35.90	13.67	8	20653	231347	79492380
Erectile dysfunction	35.81	13.67	30	20631	14634	79709093
Hyperthyroidism	35.79	13.67	36	20625	22173	79701554
Blood testosterone abnormal	35.55	13.67	9	20652	239	79723488
Electrocardiogram QT prolonged	34.62	13.67	74	20587	90312	79633415
Troponin increased	34.36	13.67	33	20628	19222	79704505
Sinusitis	34.13	13.67	5	20656	195496	79528231
Airway remodelling	34.03	13.67	9	20652	285	79723442
Hypersensitivity	33.52	13.67	13	20648	262226	79461501
Exposed bone in jaw	32.76	13.67	17	20644	3703	79720024
Cardiac septal defect	32.68	13.67	9	20652	333	79723394
Loss of libido	31.77	13.67	15	20646	2670	79721057
Joint swelling	31.23	13.67	18	20643	288628	79435099
Atopy	30.44	13.67	9	20652	431	79723296
Bone pain	30.39	13.67	53	20608	55689	79668038
Metastases to spine	30.36	13.67	17	20644	4307	79719420
Headache	29.57	13.67	80	20581	653692	79070035
Drug hypersensitivity	29.12	13.67	21	20640	298895	79424832
Therapeutic product effect decreased	29.04	13.67	4	20657	163859	79559868
Nasopharyngitis	28.67	13.67	15	20646	253866	79469861
Metastases to liver	28.62	13.67	36	20625	28278	79695449
Adrenal insufficiency	28.45	13.67	36	20625	28451	79695276
Acute myocardial infarction	28.28	13.67	62	20599	76974	79646753
Drug intolerance	27.82	13.67	17	20644	264102	79459625
Neuroendocrine carcinoma	27.57	13.67	9	20652	599	79723128
Testicular atrophy	27.47	13.67	8	20653	363	79723364
Syringe issue	26.85	13.67	18	20643	6280	79717447
Urinary tract obstruction	26.23	13.67	16	20645	4749	79718978
Cholangitis sclerosing	25.98	13.67	13	20648	2624	79721103
Product monitoring error	25.51	13.67	20	20641	8886	79714841
Blood alkaline phosphatase increased	25.39	13.67	53	20608	63611	79660116
Drug interaction	25.25	13.67	189	20472	414994	79308733
Disseminated intravascular coagulation	24.85	13.67	38	20623	35804	79687923
Radiation injury	24.69	13.67	9	20652	834	79722893
Dysuria	24.65	13.67	46	20615	50905	79672822
Radiation proctitis	24.32	13.67	6	20655	143	79723584
Decreased appetite	23.79	13.67	161	20500	342257	79381470
Neuroendocrine carcinoma of prostate	23.75	13.67	4	20657	11	79723716
Metastases to soft tissue	23.57	13.67	8	20653	601	79723126
Cystitis radiation	22.59	13.67	6	20655	193	79723534
Prostatic specific antigen decreased	22.58	13.67	5	20656	73	79723654
Conjunctival ulcer	22.09	13.67	5	20656	81	79723646
Bone disorder	22.08	13.67	26	20635	19087	79704640
Tooth extraction	21.83	13.67	20	20641	10975	79712752
Androgens increased	21.78	13.67	3	20658	0	79723727
Platelet count decreased	21.77	13.67	104	20557	194560	79529167
Bone debridement	21.71	13.67	7	20654	448	79723279
Acute coronary syndrome	21.57	13.67	27	20634	21106	79702621
Eosinophilic myocarditis	21.44	13.67	9	20652	1213	79722514
Product use issue	21.41	13.67	14	20647	209808	79513919
Lower respiratory tract infection	21.00	13.67	4	20657	129216	79594511
Haemorrhage urinary tract	20.97	13.67	11	20650	2450	79721277
Metastases to eye	20.85	13.67	6	20655	261	79723466
Phyllodes tumour	20.60	13.67	4	20657	29	79723698
Orchidectomy	20.48	13.67	4	20657	30	79723697
Breast swelling	20.39	13.67	9	20652	1371	79722356
Diabetes mellitus	20.13	13.67	55	20606	78335	79645392
Cancer pain	20.02	13.67	14	20647	5231	79718496
Urogenital haemorrhage	19.88	13.67	8	20653	969	79722758
Blood lactate dehydrogenase increased	19.75	13.67	36	20625	39134	79684593
Off label use	19.24	13.67	147	20514	907068	78816659
Rash	19.13	13.67	81	20580	578277	79145450
Hydroureter	19.02	13.67	7	20654	666	79723061
Breast tenderness	18.93	13.67	10	20651	2258	79721469
Hyperadrenalism	18.56	13.67	4	20657	51	79723676
Product name confusion	18.39	13.67	5	20656	176	79723551
COVID-19	18.26	13.67	9	20652	157665	79566062
Contraindicated product administered	18.23	13.67	9	20652	157529	79566198
Muscular weakness	18.06	13.67	86	20575	160643	79563084
Syncope	18.02	13.67	93	20568	179356	79544371
Abdominal pain upper	17.83	13.67	19	20642	223800	79499927
Microangiopathy	17.81	13.67	9	20652	1856	79721871
Spinal cord compression	17.57	13.67	14	20647	6363	79717364
Breakthrough pain	17.34	13.67	8	20653	1351	79722376
Bone cancer	17.16	13.67	9	20652	2003	79721724
Paraneoplastic dermatomyositis	17.07	13.67	4	20657	76	79723651
Cerebral infarction	17.03	13.67	37	20624	45639	79678088
Metastases to central nervous system	16.84	13.67	21	20640	16354	79707373
Vipoma	16.58	13.67	3	20658	14	79723713
Respiratory symptom	16.47	13.67	12	20649	4779	79718948
Radical prostatectomy	16.41	13.67	3	20658	15	79723712
Device leakage	16.40	13.67	17	20644	10839	79712888
Pemphigus	16.36	13.67	3	20658	99579	79624148
Osteomyelitis	16.31	13.67	30	20631	32835	79690892
Abdominal wall haematoma	16.29	13.67	12	20649	4861	79718866
Metastases to breast	16.08	13.67	5	20656	284	79723443
Subdural haematoma	15.98	13.67	29	20632	31405	79692322
Pollakiuria	15.98	13.67	32	20629	37285	79686442
Injection site induration	15.97	13.67	16	20645	9803	79713924
Allodynia	15.87	13.67	8	20653	1640	79722087
Retroperitoneal lymphadenopathy	15.69	13.67	7	20654	1093	79722634
Product dose omission issue	15.62	13.67	25	20636	247512	79476215
Penile oedema	15.60	13.67	5	20656	314	79723413
Hypogonadism	15.38	13.67	8	20653	1752	79721975
Libido decreased	15.35	13.67	12	20649	5309	79718418
Therapeutic product effect incomplete	15.07	13.67	9	20652	141636	79582091
Cough	15.00	13.67	47	20614	366742	79356985
Bone sequestrum	14.95	13.67	7	20654	1222	79722505
Bone trimming	14.88	13.67	3	20658	27	79723700
Neuroendocrine carcinoma metastatic	14.74	13.67	5	20656	375	79723352
Myoclonus	14.68	13.67	26	20635	27634	79696093
Poor peripheral circulation	14.45	13.67	10	20651	3673	79720054
Ventricular fibrillation	14.42	13.67	28	20633	31898	79691829
Eye colour change	14.35	13.67	5	20656	406	79723321
Bronchitis	14.33	13.67	8	20653	130636	79593091
Tooth loss	14.30	13.67	13	20648	7062	79716665
Anxiety	13.96	13.67	27	20634	248485	79475242
Osteitis	13.84	13.67	10	20651	3933	79719794
Formication	13.78	13.67	11	20650	5012	79718715

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L02AE51	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ENDOCRINE THERAPY HORMONES AND RELATED AGENTS Gonadotropin releasing hormone analogues
ATC	L02BB03	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ENDOCRINE THERAPY HORMONE ANTAGONISTS AND RELATED AGENTS Anti-androgens
FDA MoA	N0000000243	Androgen Receptor Antagonists
FDA EPC	N0000175560	Androgen Receptor Inhibitor
CHEBI has role	CHEBI:35497	antiandrogen
CHEBI has role	CHEBI:35610	antineoplastic agents
CHEBI has role	CHEBI:35703	Xenobiotic
CHEBI has role	CHEBI:78298	environmental contaminants
MeSH PA	D000726	Androgen Antagonists
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D006727	Hormone Antagonists

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Metastatic Prostate Carcinoma	indication
Advanced Prostatic Carcinoma	off-label use
Interstitial pneumonia	contraindication	64667001
Diabetes mellitus	contraindication	73211009	DOID:9351
Hyperglycemia	contraindication	80394007	DOID:4195
Liver function tests abnormal	contraindication	166603001
Disease of liver	contraindication	235856003	DOID:409
Drug-induced hepatitis	contraindication	235876009
Anemia	contraindication	271737000	DOID:2355
Pregnancy, function	contraindication	289908002

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	11.19	acidic
pKa2	11.84	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Androgen receptor	Nuclear hormone receptor	P10275	ANDR_HUMAN	ANTAGONIST	Ki	7.72	CHEMBL	CHEMBL
Cytochrome P450 2C19	Enzyme	P33261	CP2CJ_HUMAN		IC50	6	CHEMBL
Androgen receptor	Transcription factor		ANDR_RAT		Ki	7.85	CHEMBL
Androgen receptor	Transcription factor		ANDR_MOUSE		IC50	6.17	CHEMBL
Progesterone receptor	Transcription factor		PRGR_RABIT		IC50	5.25	CHEMBL
Progesterone receptor	Transcription factor		PRGR_RAT		Ki	5.14	CHEMBL

External reference:

ID	Source
4020950	VUID
N0000148428	NUI
D00961	KEGG_DRUG
151495	RXNORM
C0285590	UMLSCUI
CHEBI:3090	CHEBI
CHEMBL409	ChEMBL_ID
CHEMBL63560	ChEMBL_ID
DB01128	DRUGBANK_ID
C053541	MESH_SUPPLEMENTAL_RECORD_UI
2375	PUBCHEM_CID
2863	IUPHAR_LIGAND_ID
7021	INN_ID
A0Z3NAU9DP	UNII
165839	MMSL
4282	MMSL
4824	MMSL
d03850	MMSL
108766001	SNOMEDCT_US
386908000	SNOMEDCT_US
4020950	VANDF
005064	NDDF

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Bicalutamide	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6019	TABLET	50 mg	ORAL	ANDA	26 sections
Bicalutamide	HUMAN PRESCRIPTION DRUG LABEL	1	0904-6019	TABLET	50 mg	ORAL	ANDA	26 sections
Bicalutamide	HUMAN PRESCRIPTION DRUG LABEL	1	16714-816	TABLET, FILM COATED	50 mg	ORAL	ANDA	28 sections
Bicalutamide	HUMAN PRESCRIPTION DRUG LABEL	1	16729-023	TABLET	50 mg	ORAL	ANDA	26 sections
Bicalutamide	HUMAN PRESCRIPTION DRUG LABEL	1	16729-023	TABLET	50 mg	ORAL	ANDA	26 sections
bicalutamide	Human Prescription Drug Label	1	47335-485	TABLET, FILM COATED	50 mg	ORAL	ANDA	26 sections
CASODEX	HUMAN PRESCRIPTION DRUG LABEL	1	54868-4503	TABLET	50 mg	ORAL	NDA	25 sections
Bicalutamide	HUMAN PRESCRIPTION DRUG LABEL	1	54868-6133	TABLET, FILM COATED	50 mg	ORAL	ANDA	28 sections
Bicalutamide	HUMAN PRESCRIPTION DRUG LABEL	1	60429-177	TABLET, FILM COATED	50 mg	ORAL	ANDA	26 sections
Bicalutamide	HUMAN PRESCRIPTION DRUG LABEL	1	60429-177	TABLET, FILM COATED	50 mg	ORAL	ANDA	26 sections
Bicalutamide	HUMAN PRESCRIPTION DRUG LABEL	1	60429-177	TABLET, FILM COATED	50 mg	ORAL	ANDA	26 sections
Bicalutamide	HUMAN PRESCRIPTION DRUG LABEL	1	60505-2642	TABLET	50 mg	ORAL	ANDA	26 sections
bicalutamide	HUMAN PRESCRIPTION DRUG LABEL	1	62175-132	TABLET, FILM COATED	50 mg	ORAL	ANDA	26 sections
CASODEX	HUMAN PRESCRIPTION DRUG LABEL	1	62559-680	TABLET	50 mg	ORAL	NDA	27 sections
Bicalutamide	HUMAN PRESCRIPTION DRUG LABEL	1	62559-890	TABLET	50 mg	ORAL	NDA	27 sections
Bicalutamide	HUMAN PRESCRIPTION DRUG LABEL	1	63629-8308	TABLET	50 mg	ORAL	ANDA	25 sections
Bicalutamide	HUMAN PRESCRIPTION DRUG LABEL	1	63629-8308	TABLET	50 mg	ORAL	ANDA	25 sections
Bicalutamide	HUMAN PRESCRIPTION DRUG LABEL	1	63672-0005	TABLET, FILM COATED	50 mg	ORAL	ANDA	28 sections
Bicalutamide	HUMAN PRESCRIPTION DRUG LABEL	1	65841-613	TABLET, FILM COATED	50 mg	ORAL	ANDA	1 sections
Bicalutamide	HUMAN PRESCRIPTION DRUG LABEL	1	65841-613	TABLET, FILM COATED	50 mg	ORAL	ANDA	1 sections
bicalutamide	HUMAN PRESCRIPTION DRUG LABEL	1	67253-191	TABLET, FILM COATED	50 mg	ORAL	ANDA	28 sections
Bicalutamide	HUMAN PRESCRIPTION DRUG LABEL	1	68382-224	TABLET, FILM COATED	50 mg	ORAL	ANDA	28 sections
Bicalutamide	HUMAN PRESCRIPTION DRUG LABEL	1	68382-224	TABLET, FILM COATED	50 mg	ORAL	ANDA	28 sections
Bicalutamide	HUMAN PRESCRIPTION DRUG LABEL	1	70518-2993	TABLET	50 mg	ORAL	ANDA	25 sections
Bicalutamide	HUMAN PRESCRIPTION DRUG LABEL	1	71205-577	TABLET	50 mg	ORAL	ANDA	26 sections
Bicalutamide	HUMAN PRESCRIPTION DRUG LABEL	1	71205-577	TABLET	50 mg	ORAL	ANDA	26 sections